• 1
    Foster BJ, Clagett-Carr K, Leyland-Jones B, Hoth D. Results of NCI-sponsored phase I trials with carboplatin. Cancer Treat Rev 1985; 12 (Suppl A): 439.
  • 2
    Muggia FM. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989; 16: 713.
  • 3
    Christian MC. Carboplatin. In: DeVitaVTJr., HellmanS, RosenbergSA, editors. Cancer principles and practice of oncology. PPO Updates, vol. 3, no. 11. Philadelphia: JB Lippincott, 1989: 116.
  • 4
    Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986; 70: 8659.
  • 5
    Gaynon PS, Ettinger LJ, Moel D, Siegel SE, Baum ES, Krivit W, et al. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report. Cancer Treat Rep 1987; 71: 103942.
  • 6
    Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987; 5: 45963.
  • 7
    Von Hoff DD. Whither carboplatin? A replacement for or an alternative to cisplatin? J Clin Oncol 1987; 5: 16971.
  • 8
    Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors: a Children's Cancer Study Group phase II trial. Cancer 1990; 66: 24659.
  • 9
    Bertolone S, Baum ES, Krivit W, Hammond GD. A phase II study of cisplatin therapy in recurrent childhood brain tumors. J Neurooncol 1989; 7: 511.
  • 10
    Lee EJ, Egorin MJ, van Echo DA, Cohen AE, Tait N, Schiffer CA. Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J Natl Cancer Inst 1988; 80: 1315.
  • 11
    Meyers FJ, Welborn J, Lewis JP, Flynn N. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7: 1738.
  • 12
    Martinez JA, Martin G, Sanz GF, Sempere A, Jarque I, de la Rubia J, et al. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1991; 9: 3943.
  • 13
    Khan AB, D'Souza BJ, Wharam MD, Champion LAA, Sinks LF, Woo SY, et al. Cisplatin therapy in recurrent childhood brain tumors. Cancer Treat Rep 1982; 66: 201320.
  • 14
    Hruban RH, Sternberg SS, Meyers P, Fleisher M, Menendez-Botet C, Boitnott JK. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991; 9: 2638.
  • 15
    Ochs JJ, Freeman AI, Douglass HO Jr., Higby DS, Mindell ER, Sinks LF. Cis-dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62: 23945.
  • 16
    Freeman AI, Ettinger LJ, Brecher ML. Cis-dichlorodiammineplatinum (II) in childhood cancer. Cancer Treat Rep 1979; 63: 161520.
  • 17
    Pratt CB, Hayes A, Green AA, Evans WE, Senzer N, Howarth CB, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 1981; 65: 10216.
  • 18
    Nitschke R, Starling KA, Vats T, Bryan H. Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. Med Pediatr Oncol 1978; 4: 12732.
  • 19
    Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trial of cisplatin in refractory childhood cancer: Children's Cancer Study Group report. Cancer Treat Rep 1981; 65: 81522.